Non disponible en dehors du Royaume-Uni et de l'Irlande
Application
GW5074 has been used as a specific inhibitor of cRaf1 in C2 murine skeletal myoblasts, HT-29 colorectal adenocarcinoma cell line and neutrophils.
Biochem/physiol Actions
GW5074 is a cRaf1 kinase inhibitor, which is placed immediately downstream of Ras in the Motogen activated protein kinase (MAPK) signaling pathway. It elicits protection in GW5074 prevents degeneration in Huntington′s disease and also have therapeutic potential in treating neurodegenerative disorders. GW5074 in combination with anti-inflammatory drug, dexamethasone, attenuates sidestream smoke-induced airway inflammation.
Legal Information
Sold for research purposes under agreement from GlaxoSmithKline
Other Notes
light sensitive
Packaging
5, 25 mg in glass bottle
Ce produit répond aux critères suivants pour être admissible aux récompenses suivantes :